Filtered By:
Countries: Israel Health
This page shows you your search results in order of relevance. This is page number 19.
Order by Relevance | Date
Total 604 results found since Jan 2013.
ReWalk Robotics shares fall on Q4, 2018 sales miss
Shares in ReWalk Robotics (NSDQ:RWLK) fell today after the rehabilitation exoskeleton maker posted fourth quarter and full year 2018 earnings that beat loss-per-share expectations but missed wide on sales consensus from Wall Street analysts.
The Yokneam, Israel-based company posted losses of approximately $5 million, or 10¢ per share, on sales of approximately $1.6 million for the three months ended December 31, seeing losses shrink 18.6% while sales grew 4.2% when compared with its fourth quarter during the previous year.
Losses per share were just ahead of the 14¢ consensus on Wall Street, where analysts expected too ...
Source: Mass Device - February 8, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Featured MassDevice Earnings Roundup Wall Street Beat ReWalk Robotics Source Type: news
ReWalk Robotics files for exoskeleton suit clearance
ReWalk Robotics’ exo-suit designed for stroke rehabilitation.
ReWalk Robotics (NSDQ:RWLK) said it has applied to FDA for 510(k) clearance of its ReStore exoskeleton suit for gait training during stroke rehabilitation.
The Yokneam, Israel-based company designed its exo-suit to provide coordinated plantarflexion and dorsiflexion assistance to a patient’s foot and ankle. It recently won insurer reimbursement from Cigna and completed a clinical trial involving 44 patients at five rehabilitation centers in the U.S.
Get the full story on our sister site, Medical Design & Outsourcing.
The post ReWalk Robotics file...
Source: Mass Device - February 19, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: 510(k) Blog Business/Financial News Food & Drug Administration (FDA) Neurological News Well Regulatory/Compliance Robotics ReWalk Robotics Source Type: news
iSchemaView brings Rapid software to Israel
Cerebrovascular imaging software developer iSchemaView has received approval...Read more on AuntMinnie.comRelated Reading:
iSchemaView, Siemens team up on stroke imaging
Brazil clears iSchemaView's Rapid imaging software
Pulsara, iSchemaView collaborate on stroke diagnosis
iSchemaView, Samsung NeuroLogica join forces
iSchemaView wins new FDA clearance for Rapid platform
Source: AuntMinnie.com Headlines - April 9, 2019 Category: Radiology Source Type: news
iSchemaView wins approval for Rapid in Saudi Arabia
Cerebrovascular imaging software developer iSchemaView said that its Rapid...Read more on AuntMinnie.comRelated Reading:
iSchemaView brings Rapid software to Israel
iSchemaView, Siemens team up on stroke imaging
Brazil clears iSchemaView's Rapid imaging software
Pulsara, iSchemaView collaborate on stroke diagnosis
iSchemaView, Samsung NeuroLogica join forces
Source: AuntMinnie.com Headlines - April 16, 2019 Category: Radiology Source Type: news
iSchemaView opens training program for Rapid software
Cerebrovascular imaging software developer iSchemaView has launched a training...Read more on AuntMinnie.comRelated Reading:
iSchemaView wins approval for Rapid in Saudi Arabia
iSchemaView brings Rapid software to Israel
iSchemaView, Siemens team up on stroke imaging
Brazil clears iSchemaView's Rapid imaging software
Pulsara, iSchemaView collaborate on stroke diagnosis
Source: AuntMinnie.com Headlines - May 21, 2019 Category: Radiology Source Type: news
Should This Patient Be Screened for Atrial Fibrillation?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Discussion From Beth Israel Deaconess Medical Center.
Ann Intern Med. 2019 Dec 03;171(11):828-836
Authors: Burns RB, Zimetbaum P, Lubitz SA, Smetana GW
Abstract
Atrial fibrillation (AFib) is the most common type of cardiac arrhythmia, affecting 2.7 million to 6.1 million persons in the United States. Although some persons with AFib have no symptoms, others do. For those without symptoms, AFib may be detected by 12-lead electrocardiogram (ECG), single-lead monitors (such as ambulatory blood pressure monitors and pulse oximeters), or consumer devices (such as wearable monitors and smartphones). Pulse pa...
Source: Annals of Internal Medicine - December 2, 2019 Category: Internal Medicine Authors: Burns RB, Zimetbaum P, Lubitz SA, Smetana GW Tags: Ann Intern Med Source Type: research
Use of oral anticoagulation therapy in the first 3 months after the diagnosis of atrial fibrillation in Israel: a population ‐based study
ConclusionIn this real world, population ‐based cohort of patients with newly diagnosed AF, we found a lower than expected rate of OAC prescription within 3 months of diagnosis but an encouraging increase in OAC purchasing over time. Use of NOACs has risen exponentially in only a few years, accounting for a greater pool of AF patients be ing prescribed an OAC.This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - March 25, 2020 Category: Cardiology Authors: Louise Kezerle,
Meytal Avgil Tsadok,
Adi Berliner Senderey,
Moshe Hoshen,
Maya Leventer ‐Roberts,
Orna Reges,
Morton Leibowitz,
Moti Haim Tags: ORIGINAL ARTICLE Source Type: research
Aidoc secures CE Mark for pulmonary AI
Israeli artificial intelligence software developer Aidoc has secured the CE...Read more on AuntMinnie.comRelated Reading:
LucidHealth adopts Aidoc radiology AI
Aidoc secures FDA clearance for AI stroke software
Aidoc reports customer milestone
Aidoc releases full AI software package for stroke care
Aidoc nabs NY contract for AI software
Source: AuntMinnie.com Headlines - May 4, 2020 Category: Radiology Source Type: news
Cinnamon May Slow Progression To Type 2 Diabetes, Boston Study Finds
(CNN) — Cinnamon may improve blood sugar control in people with a condition known as prediabetes and may slow the progression to type 2 diabetes, according to a new pilot study of 51 people with elevated blood sugars.
“We are looking for safe, durable and cost-effective approaches to reduce the progression from prediabetes to type 2 diabetes,” said study author Dr. Giulio Romeo, a staff physician at Boston’s Joslin Diabetes Center and the division of endocrinology at Beth Israel Deaconess Medical Center. The study published Tuesday in the Journal of the Endocrine Society.
“Our 12-week study sh...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 21, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated CBSN Boston Cinnamon CNN Diabetes Source Type: news
Re-Appraisal of Echocardiographic Assessment in Patients with Pulmonary Embolism: Prospective Blinded Long-Term Follow-Up.
CONCLUSIONS: Doppler-based parameters like pulmonary flow AT, RIMP, and stroke volume, have additive value in addition to visual RV estimation to assess prognosis in patients with PE.
PMID: 33249789 [PubMed - in process]
Source: The Israel Medical Association Journal - December 1, 2020 Category: General Medicine Tags: Isr Med Assoc J Source Type: research
Apixaban in Patients with Atrial Fibrillation and Severe Renal Dysfunction: Findings from a National Registry
CONCLUSIONS: Apixaban might be a reasonable alternative to warfarin in patients with severe renal impairment.PMID:34155848
Source: The Israel Medical Association Journal - June 22, 2021 Category: General Medicine Authors: Avishay Elis Robert Klempfner Chen Gurevitz Ela Gilady Ilan Goldenberg Source Type: research
